GlassScriptPhysician profile
Luke Y Chang
NPI 1497287031
$6,913.44
in general payments reported to CMS, 2019-2025
23 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,619 · 2020: $36.04 · 2021: $818 · 2022: $321 · 2023: $1,423 · 2024: $801 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,118.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,174.01 | 2019-2020 | |
| Allergan, INC. | $818.44 | 2021 | |
| Abbvie INC. | $626.50 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Lumigan |
| Alcon Vision LLC | $619.60 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| New World Medical,INC. | $609.97 | 2023-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Glaukos Corporation | $312.55 | 2019-2025 | Idosetr, Radius, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $289.61 | 2024-2025 | Xdemvy |
| Amgen INC. | $237.71 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $207.77 | 2022-2025 | Cequa |
| Oyster Point Pharma, INC. | $177.29 | 2022-2024 | Tyrvaya |
| Abbott Laboratories | $142.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.65 | 2023 | Farxiga |
| Shire North American Group INC | $121.62 | 2019 | |
| Dompe US, INC. | $120.04 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $70.63 | 2024-2025 | Miebo, Vyzulta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $56.76 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $51.62 | 2019-2023 | |
| Thea Pharma INC. | $39.56 | 2024-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $35.65 | 2025 | Tecnis Iol |
| Sight Sciences, INC. | $27.24 | 2023-2024 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $26.08 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $14.87 | 2020 | |
| Quidel Corporation | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.